A study led by researchers at the Hospital del Mar Research Institute advances one of the most significant milestones in ...

Study in Cancer Research used mice with one copy of p53 silenced and ER gene expression doubled. Minor alterations in p53 and estrogen receptor-alpha gene expression appear to play a role in ...

Imlunestrant is a next-generation, brain-penetrant, oral selective estrogen-receptor (ER) degrader that delivers continuous ER inhibition, even in cancers with mutations in the gene encoding ERα (ESR1 ...

Many breast cancer drugs block estrogen receptors inside cancer cells. Blocking the receptors early in disease progression staves off metastasis. But most patients with advanced disease eventually ...

SAN ANTONIO – Among patients with hormone receptor-positive breast cancer treated with an aromatase inhibitor plus palbociclib (Ibrance), those who displayed a rising ESR1 mutation detected in their ...

Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma Authors retain all rights in ...

Purpose: To determine whether progesterone receptor (PgR) status provides additional value to estrogen receptor (ER) status and improves prediction of benefit from endocrine treatment among patients ...

Emerging evidence suggests there may be a critical window for estrogen therapy to protect against cognitive decline later in ...